Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption. The study aims to assess changes in disease activity, adverse events, and drug pharmacokinetics in adults with HIV.
The study tests Budigalimab and ABBV-382, investigational drugs for HIV treatment. Budigalimab is administered both intravenously and subcutaneously, while ABBV-382 is given intravenously. The goal is to evaluate their efficacy and safety in patients undergoing a temporary halt in antiretroviral therapy.
This interventional study is randomized with a parallel assignment model, and it employs quadruple masking to ensure unbiased results. The primary purpose is treatment-focused, involving multiple treatment arms, including placebo controls.
The study began on October 12, 2023, with an estimated primary completion date not yet disclosed. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and potential market impacts.
AbbVie’s study could influence its stock performance, as positive outcomes may boost investor confidence. The pharmaceutical industry closely watches such developments, given the competitive landscape in HIV treatment research.
The study is ongoing, with further details available on the ClinicalTrials portal.